Lakewood-Amedex Biotherapeutics Inc. (LABT)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2026-Mar-31
Fiscal PeriodQ1-FY2026
Close Price of Common Stock0.71$
Market Cap of Common Stock4,976,817$
QoQ%
YoY%
Common Shares Outstanding7,043,3306,995,4696,991,355
QoQ%.68%
YoY%.74%
Price to Sales
Price to Earnings
Price to Book-
Total Revenue600$
QoQ%
YoY%
TTM
TTM_QoQ%
TTM_YoY%
Gross Margin(84,448.67%)
QoQ
YoY
Operating Income(886,750$)(542,609$)
QoQ%
YoY%(63.42%)
TTM
TTM_QoQ%
TTM_YoY%
Operating Margin(147,791.67%)
QoQ
YoY
Net Income(923,291$)(539,617$)
QoQ%
YoY%(71.10%)
TTM
TTM_QoQ%
TTM_YoY%
Profit Margin(153,881.83%)
QoQ
YoY
Equity to Common Shareholders(2,841,648$)(1,964,537$)(76,233$)
QoQ(877,111$)
QoQ%(44.65%)
YoY(2,765,415$)
YoY%(3,627.58%)
Dividends Paid
Additional Paid-In Capital QoQ46,180$
Treasury Stock150,000$150,000$
QoQ0$
Goodwill
QoQ%
YoY%
Other Intangible Assets
QoQ
Amortization of Intangible Assets
Total Assets196,343$481,598$
QoQ(285,255$)
YoY
Total Liabilities3,037,991$2,446,135$
QoQ591,856$
YoY
Current Ratio.02x.13x
Total Current Assets50,626$305,389$
QoQ(254,763$)
Total Current Liabilities3,027,696$2,405,100$
QoQ622,596$
Debt to Asset Ratio15.47x5.08x
Long Term Debt
QoQ
YoY
Capital Lease Obligations131,339$
Cash and Cash Equivalents11,709$236,400$
QoQ(224,691$)
YoY
Interest Expenses
Interest Income1,078$4,307$